Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vidofludimus calcium
- Development stage
- Phase 3
- Lead developer
- Immunic
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vidofludimus calcium is an orally administered, small molecule drug under investigation for the treatment of multiple sclerosis (MS), including relapsing-remitting, secondary progressive, and primary progressive forms. It acts as a first-in-class activator of nuclear receptor-related 1 (Nurr1), providing direct neuroprotective effects by reducing neuronal loss and injury. Additionally, it selectively inhibits dihydroorotate dehydrogenase (DHODH), leading to anti-inflammatory and anti-viral effects by targeting hyperactive immune cells without suppressing normal immune function. This dual mechanism results in reduced T-cell and B-cell activity, decreased proinflammatory cytokine release, suppression of new MRI lesions in MS patients, and potential protection against viral infections such as EBV. Vidofludimus calcium has shown a favorable safety profile with low discontinuation rates in clinical trials[1][2][3][4][5][6][8].
- Other names
- vidofludimus
02
Targets
NR4A2 (Nuclear receptor subfamily 4 group A member 2)DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)
Beyond the preview
Go deeper on vidofludimus calcium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vidofludimus calcium.